Saturday 17 October 2026
Export RNLXY’s income statement to Excel — free account
Renalytix plc - Sponsored ADR
RNLXY Healthcare Health Information Services
Renalytix plc - Sponsored ADR’s revenue for fiscal 2025 (year ended June 2025) was $3.0 million, up 30.4% from fiscal 2024. Operating cash flow growth for three consecutive years.
3.50
0.11
+3.24%
Follow RNLXY
| Older periods | Jun '24 | Sep '24 | Dec '24 | Jun '25 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
2 | 3 | — | — |
| 4,476.14% | 625.67% | 0.00% | — | ||
| (241.19%) | (329.37%) | 0.00% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | — | |
Return on Tangible Assets |
947.92% | 448.66% | 0.00% | — | |
Average Days of Receivables |
111.09 | 139.33 | 0.00 | — | |
Free Cash Flow per Share |
(13.88) | (11.42) | 0.00 | — | |
Free Cash Flow |
(30.07) | (24.13) | (22.71) | — | |
Capital Expenditures |
(0.27) | — | — | — | |
| Other line items | |||||
Cash ROIC |
(4,295.86%) | 382.44% | (137.41%) | — | |
Accounts Receivable Turnover |
3.12 | 2.47 | 0.00 | — | |
Accounts Payable Turnover |
0.40 | 0.45 | 0.00 | — | |
Inventory Turnover |
10.31 | 0.00 | 0.00 | — | |
Average Days of Payables |
1,320.95 | 1,011.16 | 0.00 | — | |
Days of Inventory on Hand |
52.14 | 0.00 | 0.00 | — | |
Tax Rate |
0.00 | 0.00 | — | — | |
Research and Development Expense of Revenue |
403.91% | 314.18% | — | — | |
Selling, General and Administrative Expense of Revenue |
1,334.78% | 1,181.21% | — | — | |
Share Based Compensation of Revenue |
47.83% | 35.17% | 0.00% | — | |
Operating CF/Net income |
0.65 | 0.60 | 0.00 | — | |
Depreciation/Fixed assets |
12.50 | 12.04 | 12.25 | — | |
Capex/Depreciation |
(0.11) | 0.00 | 0.00 | — | |
Revenue per Share |
1.06 | 1.12 | — | — | |
Operating CF per Share |
(13.75) | (11.42) | 0.00 | — | |
Capex per Share |
(0.13) | 0.00 | — | — | |
Capex to Sales |
0.12 | 0.00 | — | — |
Columns are period end dates